TNFRSF9
Overview
TNFRSF9 (4-1BB, CD137) is a T-cell co-stimulatory receptor in the TNF receptor superfamily. 4-1BB agonists are being investigated as immunotherapy agents to reinvigorate anti-tumor T-cell responses in solid tumors including nasopharyngeal carcinoma (NPC).
Alterations observed in the corpus
- TNFRSF9 (4-1BB) is a T-cell co-stimulatory receptor; agonist ADG106 tested in phase I trials with no significant NPC-specific activity reported to date. PMID:24952746
- 4-1BB; immune checkpoint/co-stimulatory gene upregulated on-therapy in all patients receiving nivolumab in melanoma; nominated as combination immunotherapy target PMID:29033130
Cancer types (linked)
- NPC — 4-1BB agonist ADG106 is in phase I investigation in R/M NPC; no significant activity reported yet. PMID:24952746
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data reported in the current corpus.
Therapeutic relevance
- 4-1BB agonist ADG106 in phase I testing in NPC; rationale is to augment T-cell co-stimulation in the immunosuppressive NPC tumor microenvironment. PMID:24952746
Open questions
- Clinical activity of 4-1BB agonists in NPC remains to be established.
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:29033130
This page was processed by wiki-cli on 2026-05-15.